R8.71 BioVector™人类免疫缺陷病毒 1 型（HIV-1）复制缺陷型毒株-BioVector NTCC典型培养物保藏中心

BioVector™ R8.71 病毒是一种经过修饰的、特定的**人类免疫缺陷病毒 1 型（HIV-1）**毒株。它是一种不具感染性、复制缺陷型的病毒，被广泛应用于基因治疗和病毒学研究中。

主要特点

• 减毒的 HIV-1: 它是 HIV-1 病毒的一个改造版本。“减毒”意味着它被弱化了。这是通过删除病毒复制和致病所必需的关键辅助基因，例如 vif、vpr、vpu 和 nef，来实现的。

• 复制缺陷型: 由于缺少这些基因，R8.71 无法自行复制。这使得它成为一种不具感染性的病毒颗粒，因为它能够进入细胞，但无法产生新的病毒后代。

• 安全性: 其无法复制的特性使其成为实验室使用的安全工具，因为它造成有效感染的风险极小。

研究应用

R8.71 病毒不是用来致病的；相反，它被用作专业分析中的阳性对照。其主要应用是：

• 复制能力慢病毒（RCL）检测: 这是它的主要用途。在基因治疗中，慢病毒载体（通常源自 HIV-1）被用于将治疗基因递送到细胞中。然而，在生产过程中，存在载体组分通过重组意外产生复制能力病毒（RCL）的风险。美国食品药品监督管理局（FDA）等监管机构要求对基因治疗产品进行 RCL 污染检测。R8.71 病毒在这些检测中被用作阳性对照，以确保测试方法有效。一个有效的测试方法应该能够检测到 R8.71 病毒，从而证明该方法足够灵敏，能够发现基因治疗产品中任何潜在的 RCL 污染。

• 病毒学研究: 它可作为研究 HIV 感染早期阶段（如病毒进入宿主细胞）的工具，且没有有效感染的风险。

The BioVector™ R8.71 virus is a specific, attenuated strain of Human Immunodeficiency Virus type 1 (HIV-1). It's a non-infectious, replication-incompetent virus that is widely used in gene therapy and virology research.

Key Characteristics

• Attenuated HIV-1: It is a modified version of the HIV-1 virus. The term "attenuated" means it has been weakened. This is achieved by deleting key accessory genes, such as vif, vpr, vpu, and nef, that are essential for the virus to replicate and cause disease.

• Replication-Incompetent: Due to the missing genes, R8.71 cannot replicate on its own. This makes it a non-infectious particle, as it can enter a cell but cannot produce new viral progeny.

• Safety: Its inability to replicate makes it a safe tool for laboratory use, as it poses a minimal risk of causing a productive infection.

Research Applications

The R8.71 virus is not used to cause disease; rather, it is used as a positive control in specialized assays. Its main applications are:

• Replication-Competent Lentivirus (RCL) Assays: This is its primary use. In gene therapy, lentiviral vectors (which are often derived from HIV-1) are used to deliver therapeutic genes into cells. However, there is a risk that during the manufacturing process, a replication-competent virus (RCL) could be inadvertently created through recombination of the vector components. Regulatory agencies like the FDA require that gene therapy products be tested for RCL contamination. The R8.71 virus is used as a positive control in these assays to ensure the test is working correctly. A valid test should be able to detect the R8.71 virus, proving that it is sensitive enough to detect any potential RCL contamination in the gene therapy product.

• Virology Research: It serves as a tool for studying the early stages of HIV infection, such as viral entry into host cells, without the risk of a productive infection.

  

• 

BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947, 189-0126-8599

E-mail: biovector@163.com

http://www.biovector.net